California Healthcare Institute

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

Retrieved on: 
Monday, October 23, 2023
MITRA, Abdominal pain, Headache, Health, Menopause, Diarrhea, Liver, California Healthcare Institute, CEST, Research, Nausea, Dysmenorrhea, Growth, Pregnancy, Irritability, Partnership, Menstruation, Weakness, ASEAN, Fuji, Depression, Somatic symptom disorder, Nikkei, Brussels Stock Exchange, Birth, Patient, Back pain, Fatigue, Pharmaceutical industry, Birth control, Estetrol

The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.

Key Points: 
  • The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.
  • Fuji Pharma obtained the right to commercialize both ESTELLE® and DONESTA® in Japan and the ASEAN region in 2016, targeting a potential market of 330 million patients.
  • David Horn Solomon, CEO at Mithra: “We are very proud of our partnership with Fuji Pharma and today’s announcement marks another key milestone in Mithra’s drive for growth and achieving its mission.
  • The global dysmenorrhea market was worth EUR 257 million in 20221.

AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors

Retrieved on: 
Tuesday, August 8, 2023
Health, Biotechnology, Alembic Pharmaceuticals, Misericordia University, BIO, Turning Point, Protein, Therapy, Fortress Biotech, Chair, BioMarin Pharmaceutical, California Healthcare Institute, Dennison, EVP, Cancer, Business, United States of Europe, Pharmaceutical Research and Manufacturers of America, Pharmacy, Bristol Myers Squibb, Strategic planning, EFPIA, Bayer, Acquisition, Patient, Inc., Biotechnology Innovation Organization, Trustee, European Federation of Pharmaceutical Industries and Associations, Beerman, Johnson & Johnson, AI, Janssen Pharmaceuticals, Management, Medical device, Pharmaceutical industry, Celgene

“This is an audacious goal, and I’m grateful to have Noah and Mark join our leadership team in these key roles.

Key Points: 
  • “This is an audacious goal, and I’m grateful to have Noah and Mark join our leadership team in these key roles.
  • Noah D. Beerman is a senior executive with over 30 years of experience in the biopharmaceutical industry.
  • “I am honored to serve as Chairman of AI Proteins’ Board of Directors,” said Mr. Alles.
  • "Since establishing AI proteins, our mission has been to bring the first miniprotein therapeutics to the market to address unmet patient needs.

Centering Healthcare Institute Appoints Tammea S. Tyler as CEO

Retrieved on: 
Monday, August 7, 2023
International, California Healthcare Institute, United Nations University International Institute for Software Technology, Policy, Woman, CHI, Infant, Mortality, Health, Centring, Community health, Management, Birth control

Boston, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centering Healthcare Institute (CHI), a national non-profit organization with a mission to improve health and transform the way care is delivered, announced today the appointment of Tammea S. Tyler, MSW/MBA as Chief Executive Officer.

Key Points: 
  • Boston, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centering Healthcare Institute (CHI), a national non-profit organization with a mission to improve health and transform the way care is delivered, announced today the appointment of Tammea S. Tyler, MSW/MBA as Chief Executive Officer.
  • Under Tammea's stewardship, CHI will continue to focus on engaging multiple stakeholders to help them understand and recognize the importance of the Centering approach to transform the way that they deliver healthcare.
  • Andrea Darby-Stewart MD, CHI Board Chair, expressed great enthusiasm for the appointment of Tammea as the new Chief Executive.
  • “The Board is delighted to have appointed Tammea as our new Chief Executive.

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

Retrieved on: 
Wednesday, May 10, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Finance, Misericordia University, BIO, Turning Point, Therapy, Chair, BioMarin Pharmaceutical, Lock Haven University of Pennsylvania, California Healthcare Institute, Cancer, United States of Europe, Pharmaceutical Research and Manufacturers of America, Pharmacy, NK, Bristol Myers Squibb, EFPIA, Jack Hawkins (U.S. Marine Corps officer), Bayer, Acquisition, Patient, Inc., Biotechnology Innovation Organization, Trustee, European Federation of Pharmaceutical Industries and Associations, Johnson & Johnson, Memory, Janssen Pharmaceuticals, Pharmaceutical industry, Celgene

Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors.

Key Points: 
  • Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors.
  • Mr. Alles succeeds Natalie Mount, Ph.D., who will transition to Board Director.
  • “Mark is a highly regarded industry veteran with a wealth of operational, financial, business development, and commercial experience building and scaling oncology companies.
  • “I am honored to serve as Chair of Wugen’s Board of Directors,” said Mr. Alles.

F S Group Architects Celebrates 25 Years of Legacy-Building Design

Retrieved on: 
Friday, April 28, 2023
Developer, Gulf Coast of the United States, California Healthcare Institute, University, City, Aviation, Airport, Architectural engineering, Architecture, Creativity, Architect, AEC, Principal, Civil Aviation Department RG-1 Rohini, Interior design, Engineering, Corporation

HOUSTON, April 28, 2023 /PRNewswire-PRWeb/ -- F S Group Architects is proud to celebrate their 25th anniversary in the Architecture, Engineering, and Construction (AEC) industry. Since 1998, the firm has been providing exceptional services for complex projects across aviation, public works, space/science, and design-build.

Key Points: 
  • F S Group Architects is proud to celebrate their 25th anniversary in the Architecture, Engineering, and Construction (AEC) industry.
  • HOUSTON, April 28, 2023 /PRNewswire-PRWeb/ -- F S Group Architects is proud to celebrate their 25th anniversary in the Architecture, Engineering, and Construction (AEC) industry.
  • According to F. Sabir, F.AIA, Principal of F S Group Architects, "our team has a passion for designing practical and cost-effective facilities that are both visually appealing and operationally efficient.
  • Over the past 25 years, F S Group Architects has gained an outstanding reputation as a trusted partner for public and private sectors including Cities, Counties, Aviation Departments, Healthcare Institutions, Developers, and Corporations.

CHI Announces Leadership Transition

Retrieved on: 
Monday, December 12, 2022
Truesdale, OH, Health, Centring, Chronic pain, Public policy, Time (magazine), Diabetes, MD, Conditional sentence, California Healthcare Institute, Growth, Pregnancy, Management, Health insurance, CHI

Truesdale informed the CHI board of her intention to depart over the summer and succession planning is actively underway.

Key Points: 
  • Truesdale informed the CHI board of her intention to depart over the summer and succession planning is actively underway.
  • “The CHI board of directors is grateful for Angie’s leadership, her commitment to our mission, and dedication to CHI, its employees, the Centering community and our partners.
  • She is leaving behind a strong organization and an even stronger legacy,” said Andrea L. Darby-Stewart MD, Chair, CHI Board of Directors.
  • CHI is a national non-profit organization with a mission to improve health, transform care and disrupt inequitable systems through the Centering group model.

Oscar Health Appoints Bill Gassen and Laura Lang To Its Board of Directors

Retrieved on: 
Wednesday, December 7, 2022
Health, Technology, Managed Care, Software, Health Insurance, Benchmark, Benchmark Electronics, Tufts University, Talent, Software, Wendell Pritchett, Master of Business Administration, Individual, Bachelor of Arts in Organizational Psychology, Financial compensation, Audit, Business administration, Entrepreneurship, Bar association, California Healthcare Institute, Trustee, American Hospital Association, University, Bachelor of Science in Human Biology, NYSE, OSCR, Compensation, Medicare, Health, Publicis, Time Inc., Small group, State Bar of South Dakota, Growth, Wharton School of the University of Pennsylvania, Lawyer, Sanford Health, Management, Razorfish

Oscar Health, Inc. (Oscar) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, today announced that Bill Gassen and Laura Lang have been appointed to its Board of Directors.

Key Points: 
  • Oscar Health, Inc. (Oscar) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, today announced that Bill Gassen and Laura Lang have been appointed to its Board of Directors.
  • Ms. Lang was also appointed as Chair of the Compensation Committee of the Board and Mr. Gassen was also appointed as a member of the Nominating and Corporate Governance Committee of the Board.
  • We are thrilled to welcome Bill and Laura to Oscars Board of Directors, said Mario Schlosser, CEO and Co-Founder of Oscar.
  • Oscar Health, Inc. (Oscar) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members.

emtelligent Releases New Apps, Including AI Concordance Reporting at RSNA 2022

Retrieved on: 
Monday, November 28, 2022
McCormick Place, Organization, Work, AI, Hospital, RSNA, Knowledge, Patient safety, Patient, Radiology, NLP, Radiological Society of North America, California Healthcare Institute, Safety, Medical device, Medical imaging

VANCOUVER, BC, Nov. 28, 2022 /PRNewswire/ -- emtelligent, a leader in the development of clinical-grade natural language processing (NLP) software for healthcare organizations, today announced the continued expansion of its emtelliSuite™ family of apps on the eve of RSNA 2022, the Radiological Society of North America's annual global forum being held Nov. 27 to Dec. 1 in Chicago.

Key Points: 
  • emtelliSuite leverages emtelligent's emtelliPro NLP engine, a proprietary and purpose-built, enterprise-scale platform that enables actionable clinical insights from unstructured medical text.
  • RSNA 2022 attendees will be able to try emtelliPro and emtelliSuite apps at emtelligent's booth 4449 in the South Exhibit Hall at McCormick Place.
  • As vendors are now widely selling AI models with promises of high accuracy, hospitals, clinics, and AI vendors are discovering the need to track AI model performance.
  • Differences in imaging equipment, image protocols, and patient factors can mean a significant gap between as-advertised and real-world performance of AI models.

Europe Cervical Cancer Screening Market Report 2022: Sector Expected to be Valued at US$ 10.7 Billion in 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Medical Devices, Women, Consumer, Health, Oncology, Cell, Patient, HPV, Research, Cervical cancer, Human papillomavirus infection, COVID-19, Country, Population, US, Awareness, Woman, United Kingdom, CAGR, Non-functional testing, Uterus, Cervical, Health, Incidence, Cancer, California Healthcare Institute, Birth control, Vaccine, Growth

Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.

Key Points: 
  • Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.
  • As a result, cervical cancer screening is an essential aspect of a woman's routine health and can aid in cervical cancer prevention.
  • Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 3.3% during 2021-2027:
    The European Cervical Cancer Screening Market has grown in recent years due to an increase in the number of patients diagnosed with cervical cancer and increased awareness about cervical cancer screening programs.
  • By Country - Europe Cervical Cancer Test Market & Population Share Analysis:
    The Europe Cervical Cancer Test Market & Population Share Analysis has been done for the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, and the Netherlands in our report.

n-Lorem Foundation and Columbia University Establish Silence ALS Initiative

Retrieved on: 
Tuesday, May 3, 2022
University, Education, Other Health, Health, Philanthropy, General Health, Other Philanthropy, Research, Fund Raising, Foundation, Science, People, Hope, Motor neuron, Mutation, Department, Brain, YouTube, Instagram, Twitter, Eleanor, RNA, Glass, Columbia University, Diagnosis, Patient, Target, Columbia University Vagelos College of Physicians and Surgeons, Partnership, Neurology, Clinical trial, Amyotrophy, Physician, Spinal cord, Therapy, DNA, Surgeon, Leadership, Natural history, Efficiency, LinkedIn, ASO, California Healthcare Institute, Disease, Ionis Pharmaceuticals, Life, Genetics, Amyotrophic lateral sclerosis, CEO, Research, Biology, ALS, Department of Neurology, Xuanwu hospital, Ecosystem, Pharmaceutical industry, Dentistry, Medicine, Silence, Facebook

Silence ALS targets those nano-rare ALS patients who have a genetic mutation found in only 1 to 30 affected individuals worldwide.

Key Points: 
  • Silence ALS targets those nano-rare ALS patients who have a genetic mutation found in only 1 to 30 affected individuals worldwide.
  • The Silence ALS initiative will create the most efficient process to connect the diagnosis and treatment of patients with some of the extremely rare mutations that cause ALS.
  • Watch : n-Lorem Foundation: Creating a Better Future for Nano-Rare, One Patient at a Time
    Silence ALS is a newly formed initiative between Columbia University and n-Lorem with Target ALS as a founding donor.
  • Silence ALS plans to establish an infrastructure to enable ASO discovery and development for carriers of nano-rare ALS gene mutations.